Inside FDA HQ (File photo)
The FDA just approved the third Duchenne MD drug. And regulators still don’t know if any of them work
Last year Sarepta hit center stage with the FDA’s controversial reversal of its CRL for the company’s second Duchenne muscular dystrophy drug — after the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
